CRMD CorMedix Inc

1.9
+0.09  (+5%)
Previous Close 1.81
Open 1.83
Price To Book -21.11
Market Cap 204349115
Shares 107,552,166
Volume 1,981,180
Short Ratio 4.45
Av. Daily Volume 3,190,582

SEC filingsSee all SEC filings

  1. 8-K - Current report 19601382
  2. 8-K - Current report 19550530
  3. 8-K - Current report 19530096
  4. 8-K - Current report 19529301
  5. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 19510888

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 interim analysis July 25, 2018 by DSMB recommended trial to be stopped early as sufficient efficacy has been demonstrated. Top-line data released January 2019.
Neutrolin - LOCK-IT 100
Hemodialysis patients with central venous catheters
Phase 3 to be initiated pending funding.
Neutrolin - LOCK-IT 200
Oncology patients on Total Parental Nutrition (TPN)

Latest News

  1. Research Report Identifies SS&C Technologies, Allergan plc, CorMedix, The Allstate, Vedanta, and Lexicon Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  2. Biotech Bounce Just Getting Started
  3. Here's Why CorMedix Dropped as Much as 27.1% Today
  4. CorMedix Inc. Announces FDA Meeting Update
  5. Biotech and Cannabis Stocks That Are Emerging
  6. These Healthcare Stocks Could Surpass Investor Expectations
  7. Cormedix Inc. Announces Topline Analysis of the Full Data Set of Phase 3 Lock-It-100 Study Reinforces the Interim Results
  8. Factors of Influence in 2019, Key Indicators and Opportunity within The Hain Celestial Group, Allegheny Technologies, NVR, Greif, CorMedix, and Enzo Biochem — New Research Emphasizes Economic Growth
  9. Options Traders Expect Huge Moves in CorMedix (CRMD) Stock
  10. These 4 Healthcare Stocks Are Raising Expectations
  11. Cormedix Inc. Announces Highly Statistically Significant Topline Results For Neutrolin(R) From The Interim Analysis Of The Phase 3 Lock-It-100 Study
  12. CorMedix Inc. Announces Resignation of Member of Its Board of Directors
  13. Today's Research Reports on Trending Tickers: Incyte and CorMedix
  14. This Stock Generated 25X Returns In Just Five Years: Could BTCY Be At The Same Crossroads?
  15. Cormedix Announces Closing of $7.5 Million Senior Secured Convertible Debt Financing
  16. Implied Volatility Surging for CorMedix (CRMD) Stock Options
  17. CBD and Biotech Plays on The Rise
  18. Cormedix Receives Approval to Sell $5.4 Million of NOL Tax Benefits Through the New Jersey Economic Development Authority Program
  19. Biomedical Trends Fuel New Momentum For Healthcare Stocks; Premier Health Group, Inc. (OTC: PHGRF) (CSE: PHGI), Alliqua BioMedical, BioScrip, Coremedix
  20. Consolidated Research: 2018 Summary Expectations for Kadmon, Overstock, AECOM, Steelcase, CorMedix, and Corindus Vascular Robotics — Fundamental Analysis, Key Performance Indications

SEC Filings

  1. 8-K - Current report 19601382
  2. 8-K - Current report 19550530
  3. 8-K - Current report 19530096
  4. 8-K - Current report 19529301
  5. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 19510888
  6. 8-K - Current report 19505842
  7. 8-K - Current report 181249917
  8. 8-K - Current report 181229055
  9. 8-K - Current report 181226653
  10. 424B5 - Prospectus [Rule 424(b)(5)] 181187878